Triamcinolone Injection in the Treatment of Malar Edema

Overview

Journal Dermatol Pract Concept

Specialty Dermatology

Date 2024 May 29

PMID 38810029

Authors

Wioletta Baranska-Rybak

Zuzanna Swierczewska

Agnieszka Lemiec

Lee Walker

Affiliations

Soon will be listed here.

Abstract

Introduction: Tear-through deformities can be a detectable sign of facial aging. Over recent years, minimally invasive procedures such as hyaluronic acid filler injections have been shown to be effective in improving this area. Malar edema is the accumulation of fluid over the malar eminence persisting for 1 month or more. Given its nature, the management remains problematic. The most commonly reported treatment modality is injection with hyaluronidase.

Objectives: To determine the safety and efficacy of triamcinolone injection in the treatment of malar edema.

Methods: A total of 15 female patients with malar edema, with a mean age of 43.77 years, were treated with triamcinolone injections. The volume injected was chosen by the investigator. Prior to the triamcinolone injection, all patients had been treated with hyaluronidase, which turned out to be ineffective in all cases. Patients were asked to note all adverse effects.

Results: Satisfactory results were achieved after a single treatment session for 14 patients and after two treatments for one patient. Overall, injections with triamcinolone were well tolerated and no adverse reactions were reported.

Conclusions: Injection with triamcinolone appears to be a safe and effective option for the management of malar edema following hyaluronic acid filler injection. Nevertheless, further research with larger patient groups is compulsory.

References

Friedman S, Butler D, Pittelkow M . Perilesional linear atrophy and hypopigmentation after intralesional corticosteroid therapy. Report of two cases and review of the literature. J Am Acad Dermatol. 1988; 19(3):537-41. DOI: 10.1016/s0190-9622(88)70209-1. View

Funt D, Pavicic T . Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol. 2013; 6:295-316. PMC: 3865975. DOI: 10.2147/CCID.S50546. View

Garelik J, Babbush K, Ghias M, Cohen S . Efficacy of high-dose intralesional triamcinolone for hidradenitis suppurativa. Int J Dermatol. 2020; 60(2):217-221. DOI: 10.1111/ijd.15124. View

Song Y, Guo Y . Granulomatous Reaction to Intralesional Kenalog (Triamcinolone) Injection in Acne: A Case Report. Am J Dermatopathol. 2019; 41(9):652-654. DOI: 10.1097/DAD.0000000000001342. View

Siperstein R . Infraorbital Hyaluronic Acid Filler: Common Aesthetic Side Effects With Treatment and Prevention Options. Aesthet Surg J Open Forum. 2022; 4:ojac001. PMC: 8982019. DOI: 10.1093/asjof/ojac001. View

Hilton S, Schrumpf H, Buhren B, Bolke E, Gerber P . Hyaluronidase injection for the treatment of eyelid edema: a retrospective analysis of 20 patients. Eur J Med Res. 2014; 19:30. PMC: 4063423. DOI: 10.1186/2047-783X-19-30. View

Zhuang Z, Li Y, Wei X . The safety and efficacy of intralesional triamcinolone acetonide for keloids and hypertrophic scars: A systematic review and meta-analysis. Burns. 2021; 47(5):987-998. DOI: 10.1016/j.burns.2021.02.013. View

Funt D . Avoiding malar edema during midface/cheek augmentation with dermal fillers. J Clin Aesthet Dermatol. 2011; 4(12):32-6. PMC: 3244361. View

Siperstein R, Montes J, Speranza A . A Retrospective Review of the Safety and Efficacy of Low-dose Triamcinolone Mixed with Hyaluronic Acid Fillers to Reduce Post-injection Infraorbital Swelling. J Clin Aesthet Dermatol. 2022; 15(4):13-19. PMC: 9017664. View

10.

Sosnowski J, Cole D, Durham J, Mawhinney M . Protein kinase C mediated anti-proliferative glucocorticoid-sphinganine synergism in cultured Pollard III prostate tumor cells. J Urol. 1997; 158(1):269-74. DOI: 10.1097/00005392-199707000-00084. View

11.

Mustak H, Fiaschetti D, Goldberg R . Filling the periorbital hollows with hyaluronic acid gel: Long-term review of outcomes and complications. J Cosmet Dermatol. 2017; 17(4):611-616. DOI: 10.1111/jocd.12452. View

12.

Penfold P, Wen L, Madigan M, Gillies M, King N, Provis J . Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol. 2000; 121(3):458-65. PMC: 1905725. DOI: 10.1046/j.1365-2249.2000.01316.x. View

13.

Murthy R, Roos J, Goldberg R . Periocular hyaluronic acid fillers: applications, implications, complications. Curr Opin Ophthalmol. 2019; 30(5):395-400. DOI: 10.1097/ICU.0000000000000595. View

14.

Gallagher T, Taliercio M, Nia J, Hashim P, Zeichner J . Dermatologist Use of Intralesional Triamcinolone in the Treatment of Acne. J Clin Aesthet Dermatol. 2021; 13(12):41-43. PMC: 7819588. View

15.

Pessa J, Garza J . The malar septum: the anatomic basis of malar mounds and malar edema. Aesthet Surg J. 2009; 17(1):11-7. DOI: 10.1016/s1090-820x(97)70001-3. View

16.

Singh K, Nooreyezdan S . Nonvascular Complications of Injectable Fillers-Prevention and Management. Indian J Plast Surg. 2021; 53(3):335-343. PMC: 7822713. DOI: 10.1055/s-0040-1721872. View

17.

HOLLANDER A . Intralesional injections of triamcinolone acetonide; a therapy for dermatoses. Antibiotic Med Clin Ther (New York). 1961; 8:78-83. View

18.

Iverson S, Patel R . Dermal filler-associated malar edema: Treatment of a persistent adverse effect. Orbit. 2017; 36(6):473-475. DOI: 10.1080/01676830.2017.1337203. View

19.

Nauck M, Karakiulakis G, Perruchoud A, Papakonstantinou E, Roth M . Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998; 341(2-3):309-15. DOI: 10.1016/s0014-2999(97)01464-7. View